OmniCyte
Business Services · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
23 Business Park Dr, Branford, Connectic...Phone Number
(917) 439-7479Website
www.omnicyte.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About OmniCyte
OmniCyte is a preclinical biotechnology company dedicated to developing targeted treatments for cancer, addressing significant unmet needs in cancer therapy. The company is focused on its proprietary Immuno-Oncology Platform Technology, which includes recombinant targeted immunomodulators for various cancer indications such as ovarian cancer and small cell lung cancer. With a strong management team and a network of advisors, OmniCyte is supported by funding from Connecticut Innovations, angel investors, and various research grants. Their research and development efforts aim to create innovative immune-oncological therapeutics to improve patient outcomes.Explore more
Popular SearchesOmnicyte LLCOmniCyteSIC Code 87,873NAICS Code 54,541Show moreOmniCyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OmniCyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at OmniCyte
Check out if OmniCyte is spiking on competitors!
Product Launch: Get notified when OmniCyte launches new products
OmniCyte, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once OmniCyte has new funding data
Check if OmniCyte has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on OmniCyte recently announced quarterly report
Click to see if OmniCyte had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined OmniCyte as Masked Content
Find 2 more new buyers
Compare Similar Companies to OmniCyte
Compare insights from companies similar to OmniCyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OmniCyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OmniCyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OmniCyte.
OmniCyte financials insights
Gather financial insights about OmniCyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$20K
OmniCyte Tech Stack
A closer look at the technologies used by OmniCyte
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
OmniCyte has received an SBA PPP loan in the amount of $20,800 from The Guilford Savings Bank resulting in the retention of 1 jobs.
Funding
OmniCyte News & Media
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OmniCyte
Sign Up For FreeTo access detailed company insights
OmniCyte is a preclinical biotechnology company dedicated to developing targeted treatments for cancer, addressing significant unmet needs in cancer therapy. The company is focused on its proprietary Immuno-Oncology Platform Technology, which includes recombinant targeted immunomodulators for various cancer indications such as ovarian cancer and sm... Read More
